BR9903984A - Composição aquosa que contém peptìdio farmaceuticamente efetivo, utilização dessa composição, processo para a produção de uma composição farmacêutica para aplicação local e processo para aumentar a atividade de um polipeptìdio - Google Patents

Composição aquosa que contém peptìdio farmaceuticamente efetivo, utilização dessa composição, processo para a produção de uma composição farmacêutica para aplicação local e processo para aumentar a atividade de um polipeptìdio

Info

Publication number
BR9903984A
BR9903984A BR9903984-2A BR9903984A BR9903984A BR 9903984 A BR9903984 A BR 9903984A BR 9903984 A BR9903984 A BR 9903984A BR 9903984 A BR9903984 A BR 9903984A
Authority
BR
Brazil
Prior art keywords
polypeptide
composition
increasing
activity
pharmaceutically effective
Prior art date
Application number
BR9903984-2A
Other languages
English (en)
Other versions
BR9903984B1 (pt
Inventor
Apollon Papadimitriou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9903984A publication Critical patent/BR9903984A/pt
Publication of BR9903984B1 publication Critical patent/BR9903984B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<B><MU>COMPOSIçãO AQUOSA QUE CONTéM PEPTìDIO FARMACEUTICAMENTE EFETIVO, UTILIZAçãO DESSA COMPOSIçãO, PROCESSO PARA A PRODUçãO DE UMA COMPOSIçãO FARMACêUTICA PARA APLICAçãO LOCAL E PROCESSO PARA AUMENTAR A ATIVIDADE DE UM POLIPEPTìDIO<MV><D> Uma composição solúvel na água que contém um complexo de um polipeptídio iónico farmaceuticamente efetivo, selecionado a partir do grupo que consiste de proteínas de ouriço, proteínas morfogenéticas de osso, fatores de crescimento, eritropoietina, trombopoietina, G-CSF, interleucinas e interferonas, caracterizada pelo fato de que a dita composição contém, adicionalmente, um composto anfifílico, o dito polipeptídio e o dito composto anfifílico formando um complexo iónico, pelo que a formação do complexo não aumenta a solubilidade do dito polipeptídio, é adequada para aumentar a atividade do polipeptídio e/ou para a liberação retardada do polipeptídio.
BRPI9903984-2A 1998-09-01 1999-09-01 processo para a produção de uma composição aquosa que contém um peptìdeo farmaceuticamente efetivo. BR9903984B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98116494 1998-09-01

Publications (2)

Publication Number Publication Date
BR9903984A true BR9903984A (pt) 2001-03-13
BR9903984B1 BR9903984B1 (pt) 2011-04-19

Family

ID=8232558

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9903984-2A BR9903984B1 (pt) 1998-09-01 1999-09-01 processo para a produção de uma composição aquosa que contém um peptìdeo farmaceuticamente efetivo.

Country Status (30)

Country Link
US (3) US6867182B2 (pt)
EP (1) EP1002547B1 (pt)
JP (1) JP3664373B2 (pt)
KR (1) KR100403075B1 (pt)
CN (1) CN1325118C (pt)
AR (1) AR023044A1 (pt)
AT (1) ATE318616T1 (pt)
AU (1) AU755930B2 (pt)
BR (1) BR9903984B1 (pt)
CA (1) CA2281049C (pt)
CO (1) CO5271726A1 (pt)
DE (1) DE69930033T2 (pt)
ES (1) ES2258830T3 (pt)
GC (1) GC0000107A (pt)
HR (1) HRP990272B1 (pt)
HU (1) HUP9902952A1 (pt)
ID (1) ID22964A (pt)
IL (1) IL131626A0 (pt)
MA (1) MA26682A1 (pt)
MY (1) MY127935A (pt)
NO (1) NO994214L (pt)
NZ (1) NZ337527A (pt)
PE (1) PE20001027A1 (pt)
PL (1) PL194218B1 (pt)
RU (1) RU2180855C2 (pt)
SG (1) SG85670A1 (pt)
TR (1) TR199902103A2 (pt)
TW (1) TW570805B (pt)
YU (1) YU42399A (pt)
ZA (1) ZA995601B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
MXPA05013398A (es) * 2003-06-10 2006-03-09 Lg Life Sciences Ltd Solucion estable acuosa de eritropoyetina de origen humano, que no contiene albumina de suero.
US7622130B2 (en) * 2004-05-19 2009-11-24 Los Angeles Biomedical Research Institute at Harbor UCLA-Medical Center Methods and compositions for the non-surgical removal of fat
US20060127468A1 (en) * 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
EP1905433A1 (en) * 2005-07-15 2008-04-02 Transcu Ltd. Percutaneous absorption patch with application position indicating function, and iontophoresis device
JP2007037868A (ja) * 2005-08-05 2007-02-15 Transcutaneous Technologies Inc 経皮投与装置及びその制御方法
US20070042041A1 (en) * 2005-08-17 2007-02-22 Board Of Trustees Of The University Of Arkansas Drug-surfactant complexes for sustained release
AU2006289888B2 (en) * 2005-09-16 2010-12-02 Tti Ellebeau, Inc. Catheter type iontophoresis apparatus
JP2009509691A (ja) * 2005-09-30 2009-03-12 Ｔｔｉ・エルビュー株式会社 生体界面に多数の活性物質を送達するためのイオントフォレーシス装置
US20080033338A1 (en) * 2005-12-28 2008-02-07 Smith Gregory A Electroosmotic pump apparatus and method to deliver active agents to biological interfaces
US7848801B2 (en) * 2005-12-30 2010-12-07 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
WO2007123707A1 (en) * 2006-03-30 2007-11-01 Tti Ellebeau, Inc. Controlled release membrane and methods of use
WO2008005458A2 (en) * 2006-07-05 2008-01-10 Tti Ellebeau, Inc. Delivery device having self-assembling dendritic polymers and method of use thereof
ES2542146T3 (es) 2006-07-31 2015-07-31 Novo Nordisk A/S Insulinas extendidas PEGiladas.
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
US20080193514A1 (en) * 2006-11-02 2008-08-14 Transcu Ltd. Compostions and methods for iontophoresis delivery of active ingredients through hair follicles
FR2908414B1 (fr) * 2006-11-13 2012-01-20 Centre Nat Rech Scient Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile
EP2123259A1 (en) * 2007-01-16 2009-11-25 Hokkaido University Liposome preparation for iontophoresis having antioxidant component encapsulated therein
EP2152245B1 (en) 2007-04-30 2015-12-02 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
CA2716159A1 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
JP2010187707A (ja) * 2007-06-12 2010-09-02 Hokkaido Univ インスリンを封入したイオントフォレーシス用リポソーム製剤
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
RU2571857C2 (ru) 2008-03-18 2015-12-20 Ново Нордиск А/С Стабилизированные по отношению к протеазам ацилированные аналоги инсулина
CA2736495A1 (en) * 2008-09-10 2010-03-18 Gregory A. Smith Apparatus and method to dispense hpc-based viscous liquids into porous substrates, e.g., continuous web-based process
WO2012134540A2 (en) * 2010-10-22 2012-10-04 Vanderbilt University Injectable synthetic pur composite
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
EP2515934B1 (en) * 2009-12-22 2017-05-17 Celldex Therapeutics, Inc. Vaccine compositions
EP2675460A4 (en) 2011-02-18 2014-07-09 Kythera Biopharmaceuticals Inc TREATMENT OF FAT TISSUE UNDER CHIN
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
BR112014023068B1 (pt) 2012-03-23 2022-03-03 Amicrobe, Inc Composição aquosa para prevenir, inibir ou tratar infecção e respectivo uso
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
HUE036702T2 (hu) 2013-10-07 2018-07-30 Novo Nordisk As Inzulinanalóg új származéka
JP6776360B2 (ja) * 2015-11-04 2020-10-28 ポステック・アカデミー‐インダストリー・ファウンデーションＰｏｓｔｅｃｈ Ａｃａｄｅｍｙ‐Ｉｎｄｕｓｔｒｙ Ｆｏｕｎｄａｔｉｏｎ カチオン性分子輸送体およびタンパク質を含む、皮膚浸透用組成物
TWI700091B (zh) 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 含胰島素醫藥組成物
EP3606543A4 (en) 2017-04-06 2020-12-16 Amicrobe, Inc. COMPOSITIONS AND USES OF LOCALLY APPLIED ANTIMICROBIALS WITH IMPROVED PERFORMANCE AND SAFETY
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
AU2020254582A1 (en) * 2019-04-01 2021-09-30 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
JPS61500790A (ja) 1984-03-28 1986-04-24 シタス　コ−ポレイシヨン 微生物的に製造されたインターロイキン―２を含有する組成物
EP0179583A1 (en) * 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
LU85971A1 (fr) 1985-06-25 1987-01-13 Oreal Nouveaux composes lipidiques amphiphiles, leur procede de preparation et leurs applications,notamnent en cosmetique et en dermopharmacie
JPS62207226A (ja) 1986-03-07 1987-09-11 Sumitomo Pharmaceut Co Ltd 経鼻投与用製剤
FR2615194B1 (fr) 1987-05-11 1991-06-14 Rhone Poulenc Chimie Particules de polymere comportant, implantees a leur surface des molecules amphiphiles portant des groupes ionogenes ou reactifs, leur procede de preparation et leur application en biologie
EP0430968B1 (en) 1988-05-02 1996-11-20 PHANOS TECHNOLOGIES, Inc. Compounds, compositions and method for binding bio-affecting substances to surface membranes of bio-particles
US5688761A (en) 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
FR2694559B1 (fr) 1992-08-06 1994-10-28 Atta Nouveaux dérivés amphiphiles d'aminoacides ou de peptides, leur procédé de préparation et leur utilisation dans des préparations à usage biomédical.
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
JP3290745B2 (ja) 1993-03-31 2002-06-10 藤平 正道 単分子膜のパターン形成方法
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5789543A (en) * 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
EP0741783B1 (en) * 1993-12-30 2009-03-18 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins
US20030186357A1 (en) * 1993-12-30 2003-10-02 Philip W. Ingham Vertebrate embryonic pattern-inducing proteins, and uses related thereto
FR2714621B1 (fr) 1994-01-06 1996-02-23 Centre Nat Rech Scient Procédé de préparation de liposomes sans utilisation de solvant organique.
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5750123A (en) * 1996-06-28 1998-05-12 Chesebrough-Pond's Co., Division Of Conopco, Inc. Vitamin C delivery system
JP2002503088A (ja) * 1996-10-07 2002-01-29 ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 新規ヘッジホッグ由来ポリペプチド
HUP9904615A3 (en) 1996-10-15 2000-07-28 Seikagaku Kogyo Co Ltd Polypeptide transition metal salts and method of enhancing anti-hiv activity of polypeptide
WO1998020298A1 (en) * 1996-11-08 1998-05-14 Northern Magnetics, Inc. Sensing and controlling the location of elements of a linear motor
US5759811A (en) * 1996-11-13 1998-06-02 The Regents Of The University Of California Mutant human hedgehog gene
JPH10194987A (ja) * 1997-01-14 1998-07-28 Youtai Iwamoto 骨・軟骨形成用組成物
JPH114695A (ja) * 1997-04-25 1999-01-12 Hayashibara Biochem Lab Inc ヘッジホッグ蛋白質
US6639051B2 (en) * 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
PT917879E (pt) 1997-11-22 2002-12-31 Roche Diagnostics Gmbh Processo melhorado para estabilizacao de proteinas
EP0919618A1 (de) 1997-11-28 1999-06-02 Boehringer Mannheim Gmbh Aktive Hedgehog-Protein-Mutante, Verfahren zur Herstellung und Verwendung
EP1036092B1 (en) 1997-12-03 2005-05-11 Biogen, Inc. Hydrophobically-modified hedgehog protein compositions and methods
JP3648051B2 (ja) * 1998-02-02 2005-05-18 富士通株式会社 関連情報検索装置及びプログラム記録媒体
CA2260423C (en) 1998-02-04 2006-06-20 Kurt Lang Pharmaceutical composition of hedgehog proteins and use thereof
EP0947201B1 (en) * 1998-02-04 2006-06-28 Curis, Inc. Pharmaceutical composition of hedgehog proteins and use thereof
ATE308563T1 (de) * 1998-04-30 2005-11-15 Curis Inc Aktives hedgehog-protein-konjugat, verfahren zur herstellung und verwendung
US20050021440A1 (en) * 2003-04-04 2005-01-27 Scott Dresden Integrated dynamic pricing and procurement support for e-commerce advertising channels
WO2005029362A1 (en) * 2003-09-22 2005-03-31 Eurekster, Inc. Enhanced search engine
US20050114319A1 (en) * 2003-11-21 2005-05-26 Microsoft Corporation System and method for checking a content site for efficacy
US10515374B2 (en) * 2005-03-10 2019-12-24 Adobe Inc. Keyword generation method and apparatus

Also Published As

Publication number Publication date
KR100403075B1 (ko) 2003-10-30
US20080064854A1 (en) 2008-03-13
US8519098B2 (en) 2013-08-27
HUP9902952A1 (hu) 2000-06-28
EP1002547A1 (en) 2000-05-24
EP1002547B1 (en) 2006-03-01
DE69930033T2 (de) 2006-10-12
JP2000086532A (ja) 2000-03-28
IL131626A0 (en) 2001-01-28
BR9903984B1 (pt) 2011-04-19
ZA995601B (en) 2000-09-27
US20020028766A1 (en) 2002-03-07
TR199902103A2 (xx) 2000-04-21
ID22964A (id) 1999-12-23
SG85670A1 (en) 2002-01-15
CO5271726A1 (es) 2003-04-30
ES2258830T3 (es) 2006-09-01
PL194218B1 (pl) 2007-05-31
KR20000022777A (ko) 2000-04-25
PL335203A1 (en) 2000-03-13
NO994214L (no) 2000-03-02
CN1325118C (zh) 2007-07-11
MY127935A (en) 2007-01-31
RU2180855C2 (ru) 2002-03-27
NO994214D0 (no) 1999-08-31
NZ337527A (en) 2000-12-22
US6867182B2 (en) 2005-03-15
YU42399A (sh) 2001-05-28
HRP990272B1 (en) 2006-11-30
CA2281049C (en) 2010-11-02
DE69930033D1 (de) 2006-04-27
HU9902952D0 (en) 1999-10-28
CN1250669A (zh) 2000-04-19
GC0000107A (en) 2005-06-29
ATE318616T1 (de) 2006-03-15
US20050123610A1 (en) 2005-06-09
CA2281049A1 (en) 2000-03-01
TW570805B (en) 2004-01-11
AU755930B2 (en) 2003-01-02
AU4486699A (en) 2000-03-16
JP3664373B2 (ja) 2005-06-22
HRP990272A2 (en) 2000-06-30
AR023044A1 (es) 2002-09-04
PE20001027A1 (es) 2000-10-13
MA26682A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
BR9903984A (pt) Composição aquosa que contém peptìdio farmaceuticamente efetivo, utilização dessa composição, processo para a produção de uma composição farmacêutica para aplicação local e processo para aumentar a atividade de um polipeptìdio
NZ191867A (en) N1,n1,2,3,4,5,6-substituted-1-piperazine-carboxamides and carbothioamides
GB2210879B (en) 4h-1-benzopyran-4-one derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient
BR9708829A (pt) Processo para a preparação de um sal de magnesio de um composto heterociclico sulfinil substituido contendo uma porção imidazol sal de magnesio e composição farmaceutica
ES2017519B3 (es) Emulsiones acuosas estables al almacenamiento, de composiciones organopolisiloxanicas obtenidas por poliadicion para el recubrimiento de materiales blandos.
DE59611374D1 (de) Verfahren zur Herstellung von D,L-Methionin oder dessen Salz
HUP0102465A3 (en) Process for the production of an aqueous monoester peroxycarboxylic acid solution, the solution obtainable by this process, and its use as disinfectant
ES2128051T3 (es) Isomero de doble enlace de la equilina, procedente de la isomerizacion acida de la equilina.
DE69420827D1 (de) Verfahren zur Herstellung von wässrigen Emulsionen zur Umhüllung von festen pharmazeutischen Zusammensetzungen
BR9812453A (pt) Cristalização de açúcares
PT81229B (pt) Processo para a preparacao de 1,3-dimetil-1h-purino-2,6-dionas contendo 1h-indol-3-ilo e de composicoes farmaceuticas contendo estes compostos
DE59806082D1 (de) Verfahren zur Herstellung von substituierten 4,4&#39;-Diaminostilben-2,2&#39;-disulfonsäuren
MX26167A (es) Derivados de acido piridil-benzoico para el tratamiento de enfermedades relacionadas con lecotrino.
EA200200294A1 (ru) Сферические агломераты телитромицина, способ их получения и их применение для приготовления лекарственных форм
DE69300453T2 (de) Isoindolinon-derivat, seine herstellung und dieses enthaltende pharmazeutische zusammen setzungen.
ATE237619T1 (de) Sesquiterpen-derivate mit antiviraler aktivität
DE69903610D1 (de) Verfahren zur Herstellung von 5,5&#39;-bi-1H-Tetrazol-Salz
IT8220757A0 (it) Sale di magnesio dell&#39;acido chenodesossicolico e dell&#39;acido ursodesossicolico, processo per lasua preparazione e composizioni terapeutiche che lo contengono come principio attivo.
DE60031315D1 (de) Verfahren zur Herstellung von Derivaten von i(1,5-Diaryl)pyrazol-3-ylöpropansäure
KR970010758A (ko) 치환 4h-피란
RU93051781A (ru) Бета -фенилизосерин-(2r,3s) и его соли, способ его получения и его применения
KR940021524A (ko) 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법
HUP9601527A2 (hu) Véralvadásgátló hatású peptid-aldehid-származékok és a vegyületeket tartalmazó gyógyszerkészítmények
DE60115538D1 (de) Verfahren zur Herstellung von hochreinen 5,5&#39;-bi-1H-Tetrazoldiammoniumsalzen
IT8719093A0 (it) Derivati di esteri dell&#39;acido immidazol-1-il-carbossilico, procedimenti per la loro preparazione e composizioni fungicide che contengono il derivato come componente attivo.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: UM NOVO QUADRO REIVINDICATORIO ACRESCIDO DE 6 REIVINDICACOES FOI SUBMETIDO ATRAVES DA PETICAO NO 020090056838, DE 08/06/2009, TOTALIZANDO 13 REIVINDICACOES. COMO O NUMERO DE REIVINDICACOES ATUAIS SUPEROU 10 REIVINDICACOES, SEM QUE TENHA SIDO FEITA A DEVIDA RETRIBUICAO DAS 3 REIVINDICACOES ADICIONAIS, PEDE-SE A REQUERENTE QUE SEJA SANADA TAL IRREGULARIDADE PARA QUE SE DE PROSSEGUIMENTO AO EXAME TECNICO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/04/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: A61K 47/48; A61K 38/00; A61K 9/107; A61K 38/22; A61K 38/21; A61P 43/00.

Ipc: A61K 9/00 (2006.01), A61K 38/17 (2006.01), A61K 47

Ipc: A61K 9/00 (2006.01), A61K 38/17 (2006.01), A61K 47